Market open
ACADIA Pharmaceuticals/$ACAD
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About ACADIA Pharmaceuticals
Acadia Pharmaceuticals Inc is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecules drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Ticker
$ACAD
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
630
Website
ACAD Metrics
BasicAdvanced
$2.9B
Market cap
22.16
P/E ratio
$0.78
EPS
0.38
Beta
-
Dividend rate
Price and volume
Market cap
$2.9B
Beta
0.38
52-week high
$32.59
52-week low
$14.15
Average daily volume
1.3M
Financial strength
Current ratio
2.292
Quick ratio
1.965
Long term debt to equity
7.003
Total debt to equity
7.003
Management effectiveness
Return on assets (TTM)
8.72%
Return on equity (TTM)
27.36%
Valuation
Price to earnings (TTM)
22.155
Price to revenue (TTM)
3.059
Price to book
4.95
Price to tangible book (TTM)
6.05
Growth
Revenue change (TTM)
47.06%
Earnings per share change (TTM)
-185.10%
3-year revenue growth (CAGR)
25.12%
3-year earnings per share growth (CAGR)
-13.52%
What the Analysts think about ACAD
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for ACADIA Pharmaceuticals stock.
ACAD Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
ACAD Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
ACAD News
AllArticlesVideos
ACADIA Pharmaceuticals Inc. (ACAD) Q3 2024 Earnings Conference Call Transcript
Seeking Alpha·2 days ago
Acadia Pharmaceuticals to Announce Third Quarter Financial Results on November 6, 2024
Business Wire·3 weeks ago
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Wire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for ACADIA Pharmaceuticals stock?
ACADIA Pharmaceuticals (ACAD) has a market cap of $2.9B as of November 08, 2024.
What is the P/E ratio for ACADIA Pharmaceuticals stock?
The price to earnings (P/E) ratio for ACADIA Pharmaceuticals (ACAD) stock is 22.16 as of November 08, 2024.
Does ACADIA Pharmaceuticals stock pay dividends?
No, ACADIA Pharmaceuticals (ACAD) stock does not pay dividends to its shareholders as of November 08, 2024.
When is the next ACADIA Pharmaceuticals dividend payment date?
ACADIA Pharmaceuticals (ACAD) stock does not pay dividends to its shareholders.
What is the beta indicator for ACADIA Pharmaceuticals?
ACADIA Pharmaceuticals (ACAD) has a beta rating of 0.38. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.